Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World

E-ISSN： 2212-6988|4|2|82-92

ISSN： 2212-697x

Source： Clinical Cancer Drugs, Vol.4, Iss.2, 2018-01, pp. : 82-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity

Current Drug Metabolism, Vol. 12, Iss. 10, 2011-12 ,pp. : 932-943

Bentham Science Publishers

Access to resources Recommend Favorite

Real-World Trials to Answer Real-World Questions

By Freemantle Nick

PharmacoEconomics, Vol. 23, Iss. 8, 2005-01 ,pp. : 747-754

Adis International

Access to resources Recommend Favorite

Digoxin Toxicity: Evaluation in Clinical Practice with Pharmacokinetic Correlations

By Lecointre K.

Clinical Drug Investigation, Vol. 21, Iss. 3, 2001-03 ,pp. : 225-232

Adis International

Access to resources Recommend Favorite

Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?

By Young A.M. Daryanani S. Kerr D.J.

Clinical Pharmacokinetics, Vol. 36, Iss. 6, 1999-06 ,pp. : 391-398

Adis International

Access to resources Recommend Favorite

Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients

By van Kuilenburg André BP Maring Jan Gerard

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 799-811

Future Medicine

Access to resources Recommend Favorite